Alliance A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer
- Citation:
- Cancer Research vol 84 (9_Supplement) PO3-18-11
- Meeting Instance:
- SABCS 2023
- Year:
- 2024
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- No-Endpoint
- Analysis:
- Trial-Description-Only
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Pharmas:
- Seagen Inc
- Grants:
- U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- Ciara O'Sullivan Karla Ballman Linda McCall Tyler Zemla Anna Weiss Melissa Mitchell Victoria Blinder Nadine Tung William Irvin Jr Myounghee Lee Sailaja Kamaraju Matthew Goetz W. Fraser Symmans Virginia Borges Ian Krop Ann Partridge Lisa Carey
- Networks:
- LAPS-CO070, LAPS-CT018, LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NY016, LAPS-TX035, LAPS-WI013, MD015, NY167, SCOR
- Study
- Alliance-A011801
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: